Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Bought by Barclays PLC

Barclays PLC lifted its holdings in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 74.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 177,077 shares of the company’s stock after buying an additional 75,624 shares during the quarter. Barclays PLC’s holdings in Atea Pharmaceuticals were worth $593,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in AVIR. Intech Investment Management LLC acquired a new stake in Atea Pharmaceuticals in the 3rd quarter valued at $36,000. Dynamic Technology Lab Private Ltd purchased a new position in Atea Pharmaceuticals during the third quarter valued at $37,000. China Universal Asset Management Co. Ltd. grew its position in shares of Atea Pharmaceuticals by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 16,237 shares of the company’s stock valued at $54,000 after purchasing an additional 6,343 shares during the period. Zacks Investment Management purchased a new stake in shares of Atea Pharmaceuticals during the third quarter worth about $80,000. Finally, SG Americas Securities LLC raised its position in shares of Atea Pharmaceuticals by 117.9% during the 3rd quarter. SG Americas Securities LLC now owns 30,612 shares of the company’s stock worth $103,000 after purchasing an additional 16,561 shares during the last quarter. 86.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Atea Pharmaceuticals

In other news, Director Franklin M. Berger sold 359,606 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the completion of the sale, the director now owns 451,897 shares of the company’s stock, valued at $1,287,906.45. This represents a 44.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 17.80% of the stock is currently owned by insiders.

Atea Pharmaceuticals Trading Up 0.6 %

Shares of Atea Pharmaceuticals stock opened at $3.35 on Thursday. Atea Pharmaceuticals, Inc. has a twelve month low of $2.75 and a twelve month high of $4.60. The firm has a market capitalization of $282.95 million, a PE ratio of -1.62 and a beta of 0.20. The firm’s 50-day moving average price is $3.27 and its 200 day moving average price is $3.47.

Atea Pharmaceuticals (NASDAQ:AVIR) last released its earnings results on Thursday, November 7th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.13. During the same period in the previous year, the company posted ($0.40) earnings per share. On average, sell-side analysts predict that Atea Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Atea Pharmaceuticals Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.